Cognition Disorders Terminated Phase 2 Trials for Atomoxetine (DB00289)

IndicationStatusPhase
DBCOND0027877 (Cognition Disorders)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00548327The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) GenotypeTreatment